U.S. Markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6200+0.0101 (+1.66%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6099
Bid0.6107 x 1300
Ask0.6200 x 1100
Day's Range0.5801 - 0.6273
52 Week Range0.5600 - 2.7900
Avg. Volume2,067,391
Market Cap9.899M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.1070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

    Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announce

  • GlobeNewswire

    Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

    Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ETPHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that an abstract regarding Context’s preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation

  • GlobeNewswire

    UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)

    NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Context Therapeutics Inc. (NASDAQ: CNTX). The in-depth 26-page initiation report includes detailed information on the Context Therapeutics’ business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Promising Pipeline of Novel Sy